FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1415-1417 November 9, 2000 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Angell, M.

To the Editor: In a brief letter, it is impossible to refute all of Dr. Angell's misleading charges in her editorial on the pharmaceutical industry (June 22 issue).¹ To answer her question about accountability, the industry is accountable to physicians and their patients who are waiting for cures and better treatments, and it is also accountable to patients who need access to the medicines the industry has already developed. The large number of medicines being developed — more than a thousand are in the pipeline — proves our commitment to the first group, and company-sponsored patient-assistance programs and the industry's . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Faunce, T. A., Nasu, H. (2009). Normative Foundations of Technology Transfer and Transnational Benefit Principles in the UNESCO Universal Declaration on Bioethics and Human Rights. J Med Philos 34: 296-321 [Abstract] [Full Text]